Equity Profile

ILMN

Illumina, Inc.

Health CareLife Sciences Tools & Services$24.6B

Apr30Thu

Post-Earnings Recap

ReportedQ1-2026After Close4:05 PM EDT

Illumina Beats on EPS, Stock Up 5.3%

Metric	Actual	Expected	Surprise
EPS	$1.15	$1.05	+9.73%
Revenue	N/A	$1.1B	N/A

management commentary, guidance changes, and full analysis available with Pro.

Illumina Beats on EPS, Stock Up 5.3%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$1.15	$1.05	+9.73%
Revenue	N/A	$1.1B	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Illumina's earnings report showed a strong performance on EPS, exceeding expectations by nearly 10%. This positive surprise likely contributed to the stock's 5.3% increase in value following the announcement. However, the lack of revenue data and management commentary leaves some uncertainty about the company's overall performance and future direction.

Company Snapshot

Illumina, Inc. is a leading company in the health care sector, specializing in life sciences tools and services....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and performance relative to expectations.

$1.05

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$1.1B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Illumina, Inc. is a leading company in the health care sector, specializing in life sciences tools and services. They are known for their advanced DNA sequencing technology, which plays a crucial role in genetic research and personalized medicine.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+111.82%

Avg Stock Reaction

+1.42%

Last Quarter Recap

In the last quarter, Illumina reported an EPS of $1.35, exceeding estimates by 7.4%. Despite this positive surprise, the stock saw a slight decline the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are generally optimistic about Illumina's upcoming earnings, expecting solid performance based on previous trends. The consensus EPS estimate is $1.05, with revenue expected to be stable at $1.1 billion.

Bull Case

If Illumina beats earnings expectations again, it could reinforce investor confidence and lead to a positive stock reaction, similar to past performance.

Bear Case

On the other hand, if the company fails to meet expectations, it could trigger a negative reaction, especially given the high implied volatility in the options market.

Key Metrics to Watch

EPS

$1.05

Earnings per share is a key indicator of the company's profitability and performance relative to expectations.

Revenue

$1.1B

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Illumina achieve an EPS of $1.05 or higher?

This figure is critical as it will indicate whether the company is maintaining its growth trajectory and meeting investor expectations.

What are the revenue figures for the quarter?

Revenue performance will provide insights into market demand for Illumina's products and overall business health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Illumina's ability to leverage its recent technological advancements for higher revenue growth this quarter.

Supporting Evidence

Illumina has consistently beaten EPS estimates in the past, suggesting a pattern of underestimation.

The options market is pricing in a significant move, indicating that traders expect a more pronounced reaction than historical averages suggest.

Key Risk

If revenue growth significantly exceeds expectations, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Illumina's ability to sustain its earnings growth amidst competitive pressures in the life sciences sector.

Bull Confirmed If

An EPS of $1.10 or higher would confirm strong demand and operational efficiency.

Bear Confirmed If

An EPS below $1.00 would raise concerns about the company's growth and market position.

Pre-Earnings Positioning

Options Market

Implied Move

±9.89%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors are anticipating volatility around the earnings announcement.

Options are pricing ±9.9% while ILMN has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

31.0%

Calls (5K)P/C Ratio: 0.38Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 7 of 23 (30%)

This setup has occurred 30 times across Health Care in the last 2 years. 16 of 23 (70%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 4.2%, with a raw directional average of +0.6% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Illumina beats expectations, history suggests the stock could rise by around 0.69% on the following day, reinforcing positive sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns suggesting a potential drop of around 2.23%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or technological advancements.
2Insights into customer demand trends in the life sciences market.
3Management's commentary on competitive pressures and market share.
4Guidance on future revenue expectations and growth strategies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

CINFReported

Cincinnati Financial Corporation

RecapView

Apr27

CCKReported

Company Snapshot

Illumina, Inc. is a leading company in the health care sector, specializing in life sciences tools and services....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and performance relative to expectations.

$1.05

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$1.1B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+111.82%

Avg Stock Reaction

+1.42%

Last Quarter Recap

In the last quarter, Illumina reported an EPS of $1.35, exceeding estimates by 7.4%. Despite this positive surprise, the stock saw a slight decline the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Illumina beats earnings expectations again, it could reinforce investor confidence and lead to a positive stock reaction, similar to past performance.

Bear Case

On the other hand, if the company fails to meet expectations, it could trigger a negative reaction, especially given the high implied volatility in the options market.

Key Metrics to Watch

EPS

$1.05

Earnings per share is a key indicator of the company's profitability and performance relative to expectations.

Revenue

$1.1B

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Illumina achieve an EPS of $1.05 or higher?

This figure is critical as it will indicate whether the company is maintaining its growth trajectory and meeting investor expectations.

What are the revenue figures for the quarter?

Revenue performance will provide insights into market demand for Illumina's products and overall business health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Illumina's ability to leverage its recent technological advancements for higher revenue growth this quarter.

Supporting Evidence

Illumina has consistently beaten EPS estimates in the past, suggesting a pattern of underestimation.

The options market is pricing in a significant move, indicating that traders expect a more pronounced reaction than historical averages suggest.

Key Risk

If revenue growth significantly exceeds expectations, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Illumina's ability to sustain its earnings growth amidst competitive pressures in the life sciences sector.

Bull Confirmed If

An EPS of $1.10 or higher would confirm strong demand and operational efficiency.

Bear Confirmed If

An EPS below $1.00 would raise concerns about the company's growth and market position.

Pre-Earnings Positioning

Options Market

Implied Move

±9.89%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors are anticipating volatility around the earnings announcement.

Options are pricing ±9.9% while ILMN has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

31.0%

Calls (5K)P/C Ratio: 0.38Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 7 of 23 (30%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Illumina beats expectations, history suggests the stock could rise by around 0.69% on the following day, reinforcing positive sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns suggesting a potential drop of around 2.23%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or technological advancements.
2Insights into customer demand trends in the life sciences market.
3Management's commentary on competitive pressures and market share.
4Guidance on future revenue expectations and growth strategies.